Akari net loss widens to $4.81 million in Q2 FY26; operating loss rises to $4.6 million - AKTX News | RalliesAkari net loss widens to $4.81 million in Q2 FY26; operating loss rises to $4.6 million
A
AKTX• Quarterly loss widens as spending increases
- Akari Therapeutics posted a GAAP net loss of $4.81 million for the quarter ended June 30, 2026, widening from $1.9 million.
- Operating loss widened to $4.6 million from $3.12 million, while R&D spending rose to $2.08 million from $667,000.
- Cash totaled $7.7 million at June 30, 2026, with management expecting runway into December 2026.
- A $5.2 million May private placement closed; the White Lion $25 million equity line resale registration was declared effective July 7, 2026.
- AKTX-101 GMP manufacturing began with WuXi Biologics/XDC; first-in-human trials targeted for mid-2027, with a July Whitehawk collaboration announced.
MLM
•
